1 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
2 |
FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
|
3 |
ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
|
4 |
Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
|
5 |
MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
|
|
|
|
|
|
|